biologic

Tresiba

insulin degludec

Loss of exclusivitySeptember 2027projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameTresiba
Active ingredientinsulin degludec
Strength600UNITS/3ML (200UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2015
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.